SARS2
Basic information
Region (hg38): 19:38915266-38930763
Previous symbols: [ "SARSM" ]
Links
Phenotypes
GenCC
Source:
- hyperuricemia-pulmonary hypertension-renal failure-alkalosis syndrome (Supportive), mode of inheritance: AR
- hyperuricemia-pulmonary hypertension-renal failure-alkalosis syndrome (Limited), mode of inheritance: AR
- hyperuricemia-pulmonary hypertension-renal failure-alkalosis syndrome (Strong), mode of inheritance: AR
- hyperuricemia-pulmonary hypertension-renal failure-alkalosis syndrome (Strong), mode of inheritance: AR
- mitochondrial disease (Moderate), mode of inheritance: AR
Clinical Genomic Database
Source:
Condition | Inheritance | Intervention Categories | Intervention/Rationale | Manifestation Categories | References |
---|---|---|---|---|---|
Hyperuricemia, pulmonary hypertension, renal failure, and alkalosis syndrome | AR | General | Genetic knowledge may be beneficial related to issues such as selection of optimal supportive care, informed medical decision-making, prognostic considerations, and avoidance of unnecessary testing | Endocrine; Neurologic; Renal | 21255763 |
ClinVar
This is a list of variants' phenotypes submitted to
- not_provided (215 variants)
- Hyperuricemia,_pulmonary_hypertension,_renal_failure,_alkalosis_syndrome (146 variants)
- not_specified (72 variants)
- SARS2-related_disorder (10 variants)
- SARS2-associated_condition (2 variants)
Variants pathogenicity by type
Statistics on ClinVar variants can assist in determining whether a specific variant type in the SARS2 gene is commonly pathogenic or not. These statistics are base on transcript: NM_000017827.4. Only rare variants are included in the table.
In the table, we include only reliable ClinVar variants with their consequences to MANE Select, Mane Plus Clinical transcripts, or transcripts with TSL equals 1. Click the count to view the source variants.
Warning: slight differences between displayed counts and the number of variants in ClinVar may occur, primarily due to (1) the application of a different transcript and/or consequence by our variant effect predictor or (2) differences in clinical significance: we classify Benign/Likely benign variants as Likely benign and Pathogenic/Likely pathogenic variants as Likely pathogenic.
Effect | PathogenicP | Likely pathogenicLP | VUSVUS | Likely benignLB | BenignB | Sum |
---|---|---|---|---|---|---|
synonymous | 50 | 60 | ||||
missense | 143 | 11 | 160 | |||
nonsense | 6 | |||||
start loss | 0 | |||||
frameshift | 5 | |||||
splice donor/acceptor (+/-2bp) | 5 | |||||
Total | 3 | 7 | 164 | 61 | 1 |
Highest pathogenic variant AF is 0.0000619605
GnomAD
Source:
Gene | Type | Bio Type | Transcript | Coding Exons | Length |
---|---|---|---|---|---|
SARS2 | protein_coding | protein_coding | ENST00000600042 | 17 | 34590 |
pLI Probability LOF Intolerant | pRec Probability LOF Recessive | Individuals with no LOFs | Individuals with Homozygous LOFs | Individuals with Heterozygous LOFs | Defined | p |
---|---|---|---|---|---|---|
9.77e-10 | 0.913 | 125673 | 0 | 75 | 125748 | 0.000298 |
Z-Score | Observed | Expected | Observed/Expected | Mutation Rate | Total Possible in Transcript | |
---|---|---|---|---|---|---|
Missense | 0.249 | 310 | 323 | 0.961 | 0.0000209 | 3329 |
Missense in Polyphen | 96 | 115.98 | 0.82771 | 1198 | ||
Synonymous | -0.935 | 142 | 129 | 1.10 | 0.00000786 | 1064 |
Loss of Function | 1.87 | 19 | 30.1 | 0.631 | 0.00000157 | 320 |
LoF frequencies by population
Ethnicity | Sum of pLOFs | p |
---|---|---|
African & African-American | 0.00105 | 0.00105 |
Ashkenazi Jewish | 0.0000992 | 0.0000992 |
East Asian | 0.000217 | 0.000217 |
Finnish | 0.0000476 | 0.0000462 |
European (Non-Finnish) | 0.000330 | 0.000316 |
Middle Eastern | 0.000217 | 0.000217 |
South Asian | 0.000196 | 0.000196 |
Other | 0.00 | 0.00 |
dbNSFP
Source:
- Function
- FUNCTION: Catalyzes the attachment of serine to tRNA(Ser). Is also probably able to aminoacylate tRNA(Sec) with serine, to form the misacylated tRNA L-seryl-tRNA(Sec), which will be further converted into selenocysteinyl-tRNA(Sec). {ECO:0000250|UniProtKB:Q9N0F3}.;
- Disease
- DISEASE: Hyperuricemia, pulmonary hypertension, renal failure, and alkalosis syndrome (HUPRAS) [MIM:613845]: A multisystem disorder characterized by onset in infancy of progressive renal failure leading to electrolyte imbalances, metabolic alkalosis, pulmonary hypertension, hypotonia, and delayed development. Affected individuals are born prematurely. {ECO:0000269|PubMed:21255763}. Note=The disease is caused by mutations affecting the gene represented in this entry.;
- Pathway
- Aminoacyl-tRNA biosynthesis - Homo sapiens (human);Selenium Metabolism and Selenoproteins;tRNA Aminoacylation;Translation;Metabolism of proteins;selenocysteine biosynthesis;tRNA charging;Mitochondrial tRNA aminoacylation;Glycine, serine, alanine and threonine metabolism
(Consensus)
Recessive Scores
- pRec
- 0.154
Intolerance Scores
- loftool
- 0.681
- rvis_EVS
- -0.71
- rvis_percentile_EVS
- 14.67
Haploinsufficiency Scores
- pHI
- 0.0868
- hipred
- N
- hipred_score
- 0.403
- ghis
- 0.543
Essentials
- essential_gene_CRISPR
- E
- essential_gene_CRISPR2
- E
- essential_gene_gene_trap
- E
- gene_indispensability_pred
- E
- gene_indispensability_score
- 0.991
Gene Damage Prediction
All | Recessive | Dominant | |
---|---|---|---|
Mendelian | Medium | Medium | Medium |
Primary Immunodeficiency | Medium | Medium | Medium |
Cancer | Medium | Medium | Medium |
Mouse Genome Informatics
- Gene name
- Sars2
- Phenotype
Gene ontology
- Biological process
- tRNA aminoacylation for protein translation;seryl-tRNA aminoacylation;selenocysteinyl-tRNA(Sec) biosynthetic process
- Cellular component
- cytoplasm;mitochondrion;mitochondrial matrix
- Molecular function
- RNA binding;serine-tRNA ligase activity;ATP binding